Dr Dani Bach (formerly of Index Ventures) joins as Managing Partner, Dr Jacques Mizrahi joins in a consulting role as Venture Partner and Kadri Vunder (formerly LSVenture) as a Partner
Zurich, Switzerland – 9 January 2014 – Aravis, the first independent Swiss on-shore private equity house and an established investor in the life science and renewable energy spaces, today announced the appointment of three new members of the life science investment team.
Dr Dani Bach joins Aravis in February 2014 as Managing Partner within the life science team. Dani was previously part of the life sciences team at Geneva based venture fund, Index Ventures, having joined the firm in 2007. Dani’s investment interests have focused on protein therapeutics, neurodegeneration, and medical devices. Prior to joining Index, Dani held a research position at the Ecole Polytechnique Federal de Lausanne (EPFL), where he worked on the complex interactions between human immunodeficiency virus (HIV) and the human immune system. Dani holds a PhD in Molecular Biology from the University of Barcelona.
Dr Jacques Mizrahi began consulting Aravis as a Venture Partner in mid-2013. Dr Mizrahi has over 20 years of experience in drug discovery, drug development and translational medicine for many large pharma companies including Roche where his last position was as an Executive Leader, Cardiovascular & Metabolic Diseases. He has a PhD in pharmacology from Sherbrooke University, Quebec Canada.
Dr Kadri Vunder joined Aravis’ life science team as a Partner mid-2013. Dr. Vunder has over 10 years investment and executive management experience in the biotech, chemical and financial industries. Prior to joining Aravis, Kadri built up and managed a biotechnology oriented seed investment firm LSVenture. Kadri holds a PhD in Economics from the University of St. Gallen and scientific degrees from the Tallinn Technical University in Biotechnology and Analytical Chemistry.
Dr Simon Nebel, Managing Partner at Aravis said :“2014 will be an important year for us and we are excited to be starting it with the appointment of these high caliber team members. I am confident that their deep knowledge and proven expertise in the life science sector will be advantageous for Aravis’ future enterprises.”
Notes to Editors
Aravis is the first independent Swiss on-shore private equity house, an established investor in the life science and renewable energy spaces. We are a “hands-on” investor taking leading positions and understanding the balance between finance, commercial assets and people. With this distinct and crafted approach, we are serving over 30 leading investors including corporate, pension funds, government funds, insurance companies and family offices. Currently actively managing more than a quarter of a billion Swiss francs, we have a cumulative history of investments in over 100 companies. These have resulted in several noticeable exits including the divestment of three renewable energy companies and a number of life science reverse take-overs, listings and trade sales. Our many years of experience in Swiss investment have enabled us to establish a platform with a comprehensive offering of investment, accounting, regulatory and reporting expertise. Located in Zurich, Aravis was founded in 2001. For more information please visit: www.aravis.ch
Issued for and on behalf of Aravis.
To contact a member of the Aravis team at College Hill, email email@example.com